Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH)
about
Novel Action of Carotenoids on Non-Alcoholic Fatty Liver Disease: Macrophage Polarization and Liver HomeostasisRoles of FGFs As Paracrine or Endocrine Signals in Liver Development, Health, and DiseaseIon Channels and Oxidative Stress as a Potential Link for the Diagnosis or Treatment of Liver DiseasesNovel Molecular Mechanisms in the Development of Non-Alcoholic SteatohepatitisThe Emerging Role of Disturbed CoQ Metabolism in Nonalcoholic Fatty Liver Disease Development and ProgressionDoes Lysosomial Acid Lipase Reduction Play a Role in Adult Non-Alcoholic Fatty Liver Disease?Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An updateAstaxanthin as a Potential Protector of Liver Function: A ReviewSirtuins and nonalcoholic fatty liver diseaseOxidative stress in obesity: a critical component in human diseasesOxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosisPediatric Nonalcoholic Fatty Liver Disease: the Rise of a Lethal Disease Among Mexican American Hispanic Children.Nonalcoholic Fatty liver disease/non-alcoholic steatohepatitis in childhood: endocrine-metabolic "mal-programming".The Possible Role of Helicobacter pylori Infection in Non-alcoholic Fatty Liver Disease.Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease.NHE1 deficiency in liver: implications for non-alcoholic fatty liver disease.Plasma levels of homocysteine and cysteine increased in pediatric NAFLD and strongly correlated with severity of liver damage.P2X7 receptor as a key player in oxidative stress-driven cell fate in nonalcoholic steatohepatitis.L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway.Lowering the dietary omega-6: omega-3 does not hinder nonalcoholic fatty-liver disease development in a murine model.NADPH Oxidase-Derived Peroxynitrite Drives Inflammation in Mice and Human Nonalcoholic Steatohepatitis via TLR4-Lipid Raft RecruitmentCrude triterpenoid saponins from Ilex latifolia (Da Ye Dong Qing) ameliorate lipid accumulation by inhibiting SREBP expression via activation of AMPK in a non-alcoholic fatty liver disease model.The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH).Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress.High-fructose and high-fat diet-induced disorders in rats: impact on diabetes risk, hepatic and vascular complications.Involvement of splenic iron accumulation in the development of nonalcoholic steatohepatitis in Tsumura Suzuki Obese Diabetes mice.Effects of dietary fatty acids and cholesterol excess on liver injury: A lipidomic approachClinical Study of Serum Homocysteine and Non-Alcoholic Fatty Liver Disease in Euglycemic Patients.Cytochrome P450-2E1 promotes fast food-mediated hepatic fibrosis.Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease.The Serum Oxidative/Anti-oxidative Stress Balance Becomes Dysregulated in Patients with Non-alcoholic Steatohepatitis Associated with Hepatocellular Carcinoma.GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease.Role of the diet as a link between oxidative stress and liver diseasesControl of oxidative stress in hepatocellular carcinoma: Helpful or harmful?Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease.DNA damage response and sphingolipid signaling in liver diseases.Hepatocyte specific TIMP3 expression prevents diet dependent fatty liver disease and hepatocellular carcinoma.The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease.Serum-inducible protein (IP)-10 is a disease progression-related marker for non-alcoholic fatty liver disease.Therapeutic potential of NADPH oxidase 1/4 inhibitors.
P2860
Q26746997-25CF1837-8A26-47C6-B209-3BE5C4CD391CQ26752330-37F7C7F5-A8A5-42EF-A2F2-348CE33957B6Q26765808-5E34B32D-8D2D-49EF-B619-16056FE0D775Q26766533-68991419-5D7D-479C-BCDA-D8457AA35540Q26775025-AA29BD07-12D2-4015-A06B-21383FBB8334Q26776043-CEF23778-9368-425B-A926-E4F5868B7910Q26997059-47C68453-E2AB-486D-B2DD-B4D58A00F038Q28070358-44160036-837F-44FD-8A56-2137A3898526Q28079953-BDFDCFD4-9E2C-4947-AEAA-B903281808C0Q28082703-91DB64B0-993B-4041-9440-DEBE74091CE1Q28084150-07362665-9BC4-4E8D-8C14-78FE77779C7FQ30241654-13180E2E-B728-4087-8516-C2A2354260F8Q33580031-4B8BF000-96C3-4A28-B005-92BF47BDA36EQ33653828-23F81EB6-0E26-49D6-BE8E-4415ABA2B1FBQ33862990-C1F94777-1D69-46D4-B75F-2312AB308BEEQ33954199-28A856A0-62C7-41A9-969D-47A3374138DBQ34685694-92188828-4BDB-4D90-BCAC-D4CA0B3FFBC4Q35178036-003F5C46-1A6F-4BB8-9FD5-44DA1F9CC866Q35199067-3426BF1C-EC01-49E6-9830-A88EE17921D1Q35670899-EC73A67A-A98E-4E25-9B99-C352C6F57898Q35790133-5C0CE46E-E0AF-4880-81D1-F00F068C16A3Q35982174-7FD47F3F-9157-401C-BC1E-9C228A9CF135Q36123336-D90D87AF-3A9A-43F3-BA2B-158913A3467AQ36560010-B7220FF5-E0D7-4B30-BEF0-F20FC2FFDC33Q36616550-F3680B55-B11B-468E-869A-B1B89E17ADDEQ36638596-3CD7FC12-CF2D-4298-975A-64DE41A2543FQ37262700-49DB83C4-2084-41FB-A200-309F8F3897C5Q37406687-C62555C5-120C-4C21-8732-EB6F6F394C28Q37554361-3FD62660-5263-41BB-9057-898F2EC6D287Q37563114-F436EBCC-EE4A-46DC-8AA0-4B7E7531C28DQ37697255-45AA88B0-39AD-41D8-B902-1C3C43B56157Q38234416-B18198F2-9B4E-4488-84AD-B8FBCD00431BQ38320278-EAA5AEF0-E300-4CD1-B8F1-9FB8DA72B96DQ38466831-6D894FD4-E3C0-4CFC-BE3D-18E8EAD69191Q38602706-ED53463F-8F50-46C2-93AF-23E18F9BAD46Q38619642-FDC97870-3F98-44EF-84FE-99B97EC195C1Q38656435-06A5B89B-80DE-433C-BFD0-68F1C34BB7BAQ38725130-40AB4751-3181-442D-BB72-21227EF7F8FEQ38732142-E439576D-1931-4633-9239-AB8EB0EEFB48Q38858553-7AD010E5-ACAF-419B-95A0-DC84EB06569F
P2860
Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH)
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Multiple hits, including oxida ...... coholic steatohepatitis (NASH)
@ast
Multiple hits, including oxida ...... coholic steatohepatitis (NASH)
@en
Multiple hits, including oxida ...... coholic steatohepatitis (NASH)
@nl
type
label
Multiple hits, including oxida ...... coholic steatohepatitis (NASH)
@ast
Multiple hits, including oxida ...... coholic steatohepatitis (NASH)
@en
Multiple hits, including oxida ...... coholic steatohepatitis (NASH)
@nl
prefLabel
Multiple hits, including oxida ...... coholic steatohepatitis (NASH)
@ast
Multiple hits, including oxida ...... coholic steatohepatitis (NASH)
@en
Multiple hits, including oxida ...... coholic steatohepatitis (NASH)
@nl
P2093
P2860
P921
P3181
P356
P1476
Multiple hits, including oxida ...... coholic steatohepatitis (NASH)
@en
P2093
Akinobu Takaki
Daisuke Kawai
Kazuhide Yamamoto
P2860
P304
P3181
P356
10.3390/IJMS141020704
P407
P5008
P577
2013-10-15T00:00:00Z